Inducible costimulator (ICOS) enhances the cytolytic activity of cytokine-induced killer cells against gallbladder cancer in vitro and in vivo

Cancer Investigation

Volumn 27, Issue 3, 2009, Pages 244-250

  Wang, Jian ^a   He, Min ^a   Shi, Weijin ^a   Sha, Huifang ^b   Feng, Jiuxian ^b   Wang, Shujun ^b   Wang, Ying ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Antitumor activity; CIKs; Gallbladder cancer; ICOS modification

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; GAMMA INTERFERON; CYTOKINE; INDUCIBLE T CELL CO STIMULATOR; INDUCIBLE T-CELL CO-STIMULATOR; T LYMPHOCYTE ANTIGEN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXICITY; DISEASE SEVERITY; GALLBLADDER CANCER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN SITU HYBRIDIZATION; IN VITRO STUDY; IN VIVO STUDY; KILLER CELL; MOUSE; NECROSIS; NONHUMAN; PRIORITY JOURNAL; SEVERE COMBINED IMMUNODEFICIENCY; XENOGRAFT; ANIMAL; BIOSYNTHESIS; CYTOKINE INDUCED KILLER CELL; GALLBLADDER TUMOR; IMMUNOLOGY; MOUSE MUTANT; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINE-INDUCED KILLER CELLS; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; GALLBLADDER NEOPLASMS; HUMANS; MICE; MICE, SCID;

EID: 63349095570     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802239124     Document Type: Article

References (23)

1. Balachandran, P.; Agarwal, S.; Krishnani, N.; Pandey, C.M.; Kumar, A.; Sikora, S.S.; Saxena, R.; Kapoor, V.K. Predictors of long-term survival in patients with gallbladder cancer. J Gastrointest Surg 2006, 10, 848-854. (Pubitemid 43850375)
2. Misra, S.; Chaturvedi, A.; Misra, N.C. Gallbladder cancer. Curr Treat Options Gastroenterol 2006, 9, 95-106.
3. + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994, 153, 1687-1696.
4. Joshi, P.S.; Liu, J.Q.; Wang, Y.; Chang, X.; Richards, J.; Assarsson, E.; Shi, F.D.; Ljunggren, H.G.; Bai, X.F. Cytokine-induced killer T cells kill immature dendritic cells by TCR-independent and perforin-dependent mechanisms. J Leukoc Biol 2006, 80, 1345-1353.
5. Wang, F.S.; Liu, M.X.; Zhang, B.; Shi, M.; Lei, Z.Y.; Sun, W.B.; Du, Q.Y.; Chen, J.M. Antitumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma cells in vitro and in vivo. World J Gastroenterol 2002, 8, 464-468.
6. + cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transpl 2001, 7, 216-222.
7. Hoffman, D.M.; Gitlitz, B.J.; Belldegrun, A.; Figlin, R.A. Adoptive cellular therapy. Semin Oncol 2000, 27, 221-233.
8. Andreesen, R.; Hennemann, B.; Krause, S.W. Adoptive immunotherapy of cancer using monocyte-derived macrophages: rationale, current status, and perspectives. J Leukoc Biol 1998, 64, 419-426.
9. Hutloff, A.; Dittrich, A.M.; Beier, K.C.; Eljaschewitsch, B.; Kraft, R.; Anagnostopoulos, I.; Kroczek, R.A. ICOS is an inducible T-cell costimulator structurally and functionally related to CD28. Nature 1999, 397, 263-266. (Pubitemid 29051176)
10. Mages, H.W.; Hutloff, A.; Heuck, C.; Buchner, K.; Himmelbauer, H.; Oliveri, F.; Kroczek, R.A. Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand. Eur J Immunol 2000, 30, 1040-1047. (Pubitemid 30216219)
11. Mahajan, S.; Cervera, A.; MacLeod, M.; Fillatreau, S.; Perona-Wright, G.; Meek, S.; Smith, A.; MacDonald, A.; Gray, D. The role of ICOS in the development of CD4 T cell help and the reactivation of memory T cells. Eur J Immunol 2007, 37, 1796-1808. (Pubitemid 47065119)
12. + Th1 and Th2 responses. J Immunol 2006, 177, 2365-2372.
13. + T cells. Eur J Immunol 2006, 36, 2601-2612.
14. Okamoto, N.; Nukada, Y.; Tezuka, K.; Ohashi, K.; Mizuno, K.; Tsuji, T. AILIM/ICOS signaling induces T-cell migration/polarization of memory/effector T-cells. Int Immunol 2004, 16, 1515-1522. (Pubitemid 39341565)
15. Savas, B.; Kerr, P.E.; Pross, H.F. Lymphokine-activated killer cell susceptibility and adhesion molecule expression of multidrug resistant breast carcinoma. Cancer Cell Int 2006, 6, 24.
16. Zhang, Y.S.; Yuan, F.J.; Jia, G.F.; Zhang, J.F.; Hu, L.Y.; Huang, L.; Wang, J.; Dai, Z.Q. CIK cells from patients with HCC possess strong cytotoxicity to multidrug-resistant cell line Bel-7402/R. World J Gastroenterol 2005, 11, 3339-3345.
17. Chan, J.K.; Hamilton, C.A.; Cheung, M.K.; Karimi, M.; Baker, J.; Gall, J.M.; Schulz, S.; Thorne, S.H.; Teng, N.N.; Contag, C.H.; Lum, L.G.; Negrin, R.S. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clin Cancer Res 2006, 12, 1859-1867.
18. Koch, M.; Beckhove, P.; Opden Winkel, J.; Autenrieth, D.; Wagner, P.; Nummer, D.; Specht, S.; Antolovic, D.; Galindo, L.; Schmitz-Winnenthal, F.H.; Schirrmacher, V.; Buchler, M.W.; Weitz, J. Tumor-infiltrating T lymphocytes in colorectal cancer: tumor-selective activation and cytotoxic activity in situ. Ann Surg 2006, 244, 986-992; discussion, 992-1983 (Pubitemid 44808640)
19. Kornacker, M.; Moldenhauer, G.; Herbst, M.; Weilguni, E.; Tita-Nwa, F.; Harter, C.; Hensel, M.; Ho, A.D. Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-gamma. Int J Cancer 2006, 119, 1377-1382.
20. Okamoto, N.; Tezuka, K.; Kato, M.; Abe, R.; and Tsuji, T. PI3-kinase and MAP-kinase signaling cascades in AILIM/ICOS- and CD28-costimulated T-cells have distinct functions between cell proliferation and IL-10 production. Biochem Biophys Res Commun 2003, 310, 691-702. (Pubitemid 37188675)
21. Dong, C.; Juedes, A.E.; Temann, U.A.; Shresta, S.; Allison, J.P.; Ruddle, N.H.; Flavell, R.A. ICOS costimulatory receptor is essential for T-cell activation and function. Nature 2001, 409, 97-101.
22. Zuberek, K.; Ling, V.; Wu, P.; Ma, H.L.; Leonard, J.P.; Collins, M.; Dunussi-Joannopoulos, K. Comparable in vivo efficacy of CD28/B7, ICOS/GL50, and ICOS/GL50B costimulatory pathways in murine tumor models: IFN-gamma-dependent enhancement of CTL priming, effector functions, and tumor specific memory CTL. Cell Immunol 2003, 225, 53-63.
23. Kaneda, H.; Takeda, K.; Ota, T.; Kaduka, Y.; Akiba, H.; Ikarashi, Y.; Wakasugi, H.; Kronenberg, M.; Kinoshita, K.; Yagita, H.; Okumura, K. ICOS costimulates invariant NKT cell activation. Biochem Biophys Res Commun 2005, 327, 201-207. (Pubitemid 40051371)